Press Releases

Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the Inc. 5000 2022 list of fastest growing private companies for the fourth year in a row. To qualify, companies must have been founded and generating revenue by March 31, 2018. Ranking in the list is determined by the percentage revenue growth from 2018 to 2021, with minimums set for each year.

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces a new peer-reviewed publication titled, “SneakPeek Early Gender Test: The Earliest and Most Accurate Method for Fetal Sex Determination at 6-Weeks’ Gestation” in the Clinics in Mother and Child Health journal.

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, achieved a milestone of over 130 distributors of its SneakPeek Clinical test in Canada, providing nationwide coverage for Canadians.

Gateway Genomics, leading developer of direct-to-consumer genetic tests that give families insight into their future children, achieved a milestone of over 1,500 distributors of its SneakPeek Clinical test across the US, UK, and Canada. The rate of signup accelerated when the company added SneakPeek Snap to its clinical offerings.

Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces the launch of the new SneakPeek Snap into all clinical partner locations in the US. SneakPeek Snap is a microneedle-based device that collects capillary blood through the upper arm rather than through the fingertip or venipuncture, found to be completely painless by 90% of users in a recent clinical study. The automated, self-contained nature of SneakPeek Snap also makes it easy to self-administer; 90% of users in the same study found it very easy to use.

Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, reached 500,000 SneakPeek Early Gender DNA Tests sold last month, continuing the company’s rapid growth trajectory.

Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces a new publication titled, “Accurate Fetal Sex Determination from Maternal Blood at 7 Weeks Gestation” in the Journal of Pregnancy & Child Health. In the study, DNA blood samples were collected from 125 women at 7 weeks gestation across 12 independent clinics in the United States. Cell-free fetal DNA (cffDNA) was extracted and run through the SneakPeek test process, which looks for male chromosomes.

Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces that the Mom’s Choice Award Among the Best in Family-Friendly Products was awarded to SneakPeek Gender DNA Test. To be considered for the award, five SneakPeek Gender DNA At-Home test kits were submitted for use to Mom’s Choice, which matched the products with appropriate evaluators in the MCA database.

Gateway Genomics, a leading developer of direct-to-consumer genetic tests that give families insight into their future children, announces inclusion in the Inc. 5000 2021 list of fastest growing private companies for the third straight year. To qualify, companies must have been founded and generating revenue by March 31, 2017. Ranking in the list is determined by the percentage revenue growth from 2017 to 2020, with minimums set for each year.

Gateway Genomics, market leader of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces the launch of the new SneakPeek Brand Affiliates program that allows partners and supporters to promote SneakPeek Gender or Traits At-home products and receive a commission.